Key insights
- Medtronic's stock hit a 52-week low amid investor concerns, despite a high dividend yield and positive Fair Value analysis. Recent CE mark approval for Stealth AXiS in Europe is a positive catalyst, offset by a disclosed cybersecurity breach and lowered price targets from Jefferies and UBS. Overall, the news leans slightly negative for near-term US equity market sentiment towards MDT.
Medtronic PLC stock reached a 52-week low, hitting $79.93, reflecting ongoing challenges for the medical device company. The $102.76 billion market cap firm has seen its shares decline 14% year-to-date, with the stock trading nearly 25% below its 52-week high of $106.33. The decline in stock price indicates investor concerns or market conditions impacting Medtronic’s financial outlook. Yet the company maintains financial strengths, including a 3.47% dividend yield and an impressive 50-year streak of consecutive dividend payments, according to InvestingPro data. The platform’s Fair Value analysis suggests the stock may be undervalued at current levels. For deeper insights, investors can access Medtronic’s comprehensive Pro Research Report, one of 1,400+ available on InvestingPro. As the company navigates these hurdles, stakeholders will be watching closely for any strategic moves or market developments that could influence its stock trajectory in the coming months.
In other recent news, Medtronic has received CE mark approval for its Stealth AXiS surgical system, allowing the company to market the integrated surgical platform across Europe. This development follows earlier U.S. FDA clearances for the system, which combines planning, navigation, and robotics for spine and cranial procedures. Additionally, Medtronic disclosed a cybersecurity breach affecting its IT systems, but assured that there was no impact on its products, patient safety, or operations. The company has engaged external cybersecurity experts to assist with investigation and remediation efforts.
Medtronic also reported that a cyberattack on its computer systems did not affect its products or operations, and is not expected to materially impact its business or financial results. On the financial front, Jefferies lowered its price target for Medtronic to $95 from $108, maintaining a Hold rating, due to IPO timing and related expenses. Similarly, UBS reduced its price target to $90 from $104, citing the impact of the MMED IPO on Medtronic’s earnings. Both firms have adjusted their earnings estimates to reflect these developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.